From: The prognostic value of quality of life in atrial fibrillation on patient value
 | AFEQT score at baseline | ||||
---|---|---|---|---|---|
 | First quartile (Q1) (4.63 to ≤ 57.41) | Second quartile (Q2)(> 57.41 to ≤ 75.93) | Third quartile (Q3) (> 75.93 to ≤ 90.74) | Fourth quartile (Q4)(> 90.74 to 100) | p-value |
 | n (%) | n (%) | n (%) | n (%) |  |
Total* | 239 (24.6%) | 238 (24.5%) | 248 (25.6%) | 245 (25.3%) | - |
Gender | Â | Â | Â | Â | Â |
Man | 108 (45.2%) | 136 (57.1%) | 141 (56.9%) | 175 (71.4%) | Â |
Woman | 131 (54.8%) | 102 (42.9%) | 107 (43.1%) | 70 (28.6%) | < 0.001 |
Age | Â | Â | Â | Â | Â |
mean (SD) | 70.0 (10.4) | 69.7 (9.7) | 69.1 (9.6) | 69.1 (9.1) | 0.667 |
Type of AF | Â | Â | Â | Â | Â |
Paroxysmal | 132 (62.9%) | 156 (74.6%) | 163 (73.1%) | 140 (66.0%) | Â |
Persistent | 78 (37.1%) | 53 (25.4%) | 60 (26.9%) | 72 (34.0%) | 0.024 |
CHA2DS2-VASc score (T0) | Â | Â | Â | Â | Â |
0–1 | 54 (22.6%) | 52 (22.3%) | 66 (26.8%) | 79 (32.5%) |  |
2+ | 185 (77.4%) | 181 (77.7%) | 180 (73.2%) | 164 (67.5%) | 0.037 |
HAS-BLED (T0) | Â | Â | Â | Â | Â |
0–1 | 104 (51.0%) | 120 (62.8%) | 120 (60.0%) | 117 (59.1%) |  |
2+ | 100 (49.0%) | 71 (37.2%) | 80 (40.0%) | 81 (40.9%) | 0.095 |
OSAS | Â | Â | Â | Â | Â |
No | 225 (94.1%) | 229 (96.2%) | 232 (93.9%) | 233 (95.1%) | Â |
Yes | 14 (5.9%) | 9 (3.8%) | 15 (6.1%) | 12 (4.9%) | 0.656 |
Diabetes mellitus | Â | Â | Â | Â | Â |
No | 202 (84.5%) | 203 (85.3%) | 217 (87.5%) | 215 (87.8%) | Â |
Yes | 37 (15.5%) | 35 (14.7%) | 31 (12.5%) | 30 (12.2%) | 0.663 |
BMIa | Â | Â | Â | Â | Â |
< 25 | 55 (26.1%) | 68 (33.7%) | 66 (32.8%) | 70 (34.3%) |  |
≥ 25 | 156 (73.9%) | 134 (66.3%) | 135 (67.2%) | 134 (65.7%) | 0.239 |
Hypertension | Â | Â | Â | Â | Â |
No | 97 (40.6%) | 103 (43.3%) | 105 (42.3%) | 122 (49.8%) | Â |
Yes | 142 (59.4%) | 135 (56.7%) | 143 (57.7%) | 123 (50.2%) | 0.187 |
Heart failure | Â | Â | Â | Â | Â |
No | 221 (92.5%) | 229 (96.2%) | 243 (98.0%) | 240 (98.4%) | Â |
Yes | 18 (7.5%) | 9 (3.8%) | 5 (2.0%) | 4 (1.6%) | 0.002 |
Malignancy | Â | Â | Â | Â | Â |
No | 209 (87.4%) | 210 (88.6%) | 222 (89.5%) | 214 (87.7%) | Â |
Yes | 30 (12.6%) | 27 (11.4%) | 26 (10.5%) | 30 (12.3%) | 0.890 |
Chronic lung disease | Â | Â | Â | Â | Â |
No | 207 (87.3%) | 212 (89.1%) | 229 (26.2%) | 227 (93.0%) | Â |
Yes | 30 (12.7%) | 26 (10.9%) | 19 (7.7%) | 17 (7.0%) | 0.107 |
EHRA at baseline | Â | Â | Â | Â | Â |
Mean (SD) | 2.29 (0.90) | 1.85 (0.83) | 1.69 (0.80) | 1.42 (0.65) | < 0.001 |
Location of diagnosis | Â | Â | Â | Â | Â |
General practitioner | 79 (33.6%) | 62 (26.3%) | 79 (32.1%) | 78 (31.8%) | Â |
Hospital | 156 (66.4%) | 174 (73.7%) | 167 (67.9%) | 167 (68.2%) | 0.328 |